Bayer Bolsters India Focus with Expanded Therapies and Healthcare Ecosystem

German multinational pharmaceutical and biotechnology firm Bayer aims to bolster its presence in India by broadening its range of therapies and increasing collaborations throughout the healthcare ecosystem. Bayer has launched various treatments to tackle particular health issues in these regions. Recent product introductions, such as Kerendia (finerenone), Verquvo (vericiguat), and Nubeqa (darolutamide), exemplify this approach. Kerendia aids in preventing or postponing kidney failure in individuals with diabetes, whereas Verquvo aims to lower hospitalisation rates in those with deteriorating heart failure. Nubeqa, a therapy for prostate cancer, has broadened its approved uses since its introduction in July 2022. 

“Our focus in India’s pharmaceutical market is on addressing critical healthcare needs across key therapeutic areas such as cardiovascular, diabetes, kidney health, women’s health, oncology, and ophthalmology,” said Shweta Rai, Managing Director India and Country Division Head South Asia, Bayer Pharmaceuticals.

“Currently, we are conducting approximately 17 clinical trials in India, spanning Phase II, III, and IV, with nearly 4,000 Indian participants. This ensures that our treatments are both effective and safe for the local population,” Rai explained.

India holds an important position in Bayer’s worldwide activities, especially in the areas of research and development. The Global Capability Centre in Hyderabad of the company plays a role in R&D, data science, and AI-based healthcare solutions, aiding global Phase II and III trials.